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Abstract 
Renal cell carcinomas make up two to three percent of all malignancies in adults, and are 
the cause of over 102,000 deaths worldwide each year (Cohen & McGovern, 2005). It is the 
most common kidney tumor, and the incidence of renal cell carcinoma is slowly on the rise. 
Percutaneous radiofrequency ablations and percutaneous cryoablations are becoming an 
alternative treatment and are a successful treatment option in the fight against renal cell 
carcinoma (Park, Anderson, & Matsumoto, 2006). 
The purpose of this study is to compare the efficacy of percutaneous radiofrequency 
ablations and percutaneous cryoablations of renal cell carcinoma in terms of the pain associated 
with each procedure as measured by the amount of intra-operative analgesics required, the 
amount of post-operative analgesics required; and the length of time required to perform the 
ablation procedure. 
A total of 34 patients over the age of 18 that underwent percutaneous cryoablations or 
percutaneous radiofrequency ablations were included in this study. Using a Chi-Square test of 
significance (p=.05), no significant relationships were identified in reference to the dose of intra-
operative analgesics and post-operative analgesics administration and the type of ablation. 
However, a significant correlation identified utilizing a Point Bi-serial test of significance 
comparing the procedure lengths of percutaneous cryoablations and percutaneous radiofrequency 
ablations. 
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Chapter 1 
Introduction 
Percutaneous radiofrequency ablations and cryoablations are a minimally invasive way 
to treat renal cell carcinomas, and preserve kidney function (Fergany, 2005), Percutaneous 
radiofrequency ablations are performed by inserting a probe into the tumor site and inducing a 
high electrical current that heats up the tumor and eventually destroys it. Cryoablative therapies 
do the exact opposite, Probes are inserted into the tumor and high pressure argon and nitrogen 
gases are circulated throughout the probes. This allows the core temperature of the tumor to 
reach as low as -190 degrees Celsius, forming ice crystallization on the tumor which necrosis the 
tumor (Lehman & Landman, (2), 2008). The probes are then slightly heated, during the thaw 
cycle, causing the tumor to go through a state of ischemia Lehman & Landman, (2), 2008). 
Many freeze-thaw cycles are used during cryoablations to insure cell death ofthe tumor 
(Fergany, 2005; Lehman & Landman, (2), 2008). 
Percutaneous radiofrequency and cryoablative therapies are nephron sparing alternatives 
for the treatment of renal cell carcinoma. These ablative therapies are appealing to patients who 
have a solitary kidney, those who are poor surgical risks, immunocompromised patients, and to 
patients with coagulation problems (Park, Anderson, & Matsumoto, 2006; Permpongkosol, 
Nielsen, & Solomon, 2006; Lehman & Landman, (2), 2008; Breen, Rutherford, Stedman, et aI, 
2007). By offering percutaneous ablative treatments, it allows the patients to become surgical 
candidates as a way to treat their cancer. 
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Problem Statement 
Renal cell carcinoma is the seventh most common cancer in men, and the ninth most 
common in women in the United States. It is responsible for more than 102,000 deaths a year, 
and is prevalent in more than 209,000 cancer cases per year. It seems to be more prevalent in 
males by a ratio of2:1 (Cohen & McGovern, 2005). The incidence of renal cell carcinoma has 
been increasing over the years, as well as the mortality rates associated with this disease. Some 
of the risk factors associated with renal cell carcinoma include smoking, obesity, and 
hypertension. Signs and symptoms of renal cell carcinoma include hematuria, flank pain, and a 
palpable abdominal mass. Treatments for renal cell carcinoma include radical nephrectomy, 
partial nephrectomy, ablations, and chemotherapy (Cohen & McGovern, 2005; Fergany, 2005). 
Review of Literature 
Renal cell carcinomas make up two to three percent of all malignancies in adults, and are 
the cause of over 102,000 deaths worldwide each year (Cohen & McGovern, 2005). It is the 
most common kidney tumor, and the incidence of renal cell carcinoma is slowly on the rise. 
Treatment of renal cell carcinomas include chemotherapy, radical extirpative surgeries, and more 
recently, nephron-sparing procedures such as laparoscopic partial nephrectomy, open partial 
nephrectomy, and percutaneous needle ablative therapies (Cohen & McGovern, 2005; Fergany, 
2005). Percutaneous radio frequency ablations and percutaneous cryoablations are becoming an 
alternative treatment for patients whose bodies are unable to handle a significant surgery. 
Percutaneous ablative therapies are a successful treatment option in the fight against renal cell 
carcinoma, which preserves renal function, as well as decreasing postoperative morbidity, and 
decreasing the amount of recovery time (Park, Anderson, & Matsumoto, 2006). 
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Ablative therapies such as radiofrequency ablations and cryoablations are appealing to 
those patients who have a solitary kidney, those with multiple comorbiditiesm, as well as many 
immunocompromised patients (Park, Anderson, & Matsumoto, 2006; Permpongkosol, Nielsen, 
& Solomon, 2006). Tumor ablative procedures significantly reduce the amount of blood loss 
during a surgery which makes a patient with a history of coagulopathy an immediate candidate 
(Lehman & Landman, (I), 2008; Breen, Rutherford, Stedman, B., et aI, 2007). Percutaneous 
tumor ablations are being used more frequently in the treatment of small cell renal carcinoma, 
and primarily focusing on patients with a tumor size of less than four centimeters (Fergany, 
2005; Park, Anderson, & Matsumoto, 2006). When tumor size grows larger than four 
centimeters it becomes very difficult to fully ablate the tumor in one treatment, and multiple 
treatments are required (Arima, Yamakado, Kinbara, et aI., 2007). Tumor location is the 
primary deciding factor of whether a patient is a good candidate for an ablative procedure (Park, 
Anderson, & Matsumoto, 2006). Tumors that are situated posterior have the greatest success 
rate for percutaneous cryoablations and radiofrequency ablations. When the tumor sits anteriorly 
in the body it becomes difficult to percutaneously ablate the tumor. In such cases the alternative 
is to execute the procedure laprascopically in fear of injuring a bowel, organ or ureter (Park, 
Anderson, & Matsumoto, 2006; Breen, Rutherford, Stedman, et aI, 2007; Boss, Clasen, Kuczyk, 
et aI., 2007). Exophytic tumors seem to be less complicated to ablate using radiofrequency 
because the insulation of the fat allows for a higher ablation temperature. Contrarily, it becomes 
more difficult to ablate tumors that are situated close to large blood vessels using radio frequency 
(Boss, Clasen, Kuczyk, et aI., 2007). This is due to the fact that there is a great deal of heat 
dissipation through the blood flow in the vessels, known as the heat-sink effect (Fergany, 2005; 
Boss, Clasen, Kuczyk, et aI., 2007). So, while many patients may be a good candidate for 
6 
percutaneous ablative procedures due their poor surgical risk, final decisions is based on the 
tumor size and tumor location. 
Percutaneous radiofrequency ablation incorporates the use of a high frequency probe that 
generates an electrical current (Lehman & Landman, (2), 2008). The probe is placed in the 
targeted tumor where it delivers a frequency of 400 to 500 kilohertz, which can produce 
temperatures ranging from 60 degrees Celsius to 110 degrees Celsius (Lehman & Landman, (2), 
2008; Breen, Rutherford, Stedman, et ai, 2007). It is these excessive temperatures that cause a 
coagulative necrosis of the tumor (Fergany, 2005; Breen, Rutherford, Stedman, et ai, 2007). 
Contrarily, cryoablation uses the Joule-Thompson effect and circulates high pressure argon or 
nitrogen gas to achieve temperatures as low as -\90 degrees Celsius (Lehman & Landman, (2), 
2008). Renal cell carcinomas are destroyed by using freeze-thaw cycles at temperatures ranging 
from -20 degrees Celsius to -40 degrees Celsius (Fergany, 2005; Lehman & Landman, (2), 
2008). This temperature at the core of the tumor is achieved by extending the targeted site of 
ablation I centimeter passed the borders of the tumor (Breen, Rutherford, Stedman, et ai, 2007). 
When the probe is inserted into the tumor it causes a direct toxicity to the cells because of the ice 
crystallization that the probes form. Once the thaw cycle reaches the tumor, the tumor then goes 
through a state of ischemia where the blood flow is significantly reduced (Lehman & Landman, 
(1),2008). The success of the thaw cycle is based on the cooling rate. As the rate of the cooling 
cycle increases, so does the production of intracellular ice, which is the destructive element of 
cryoablations (Lehman & Landman, (2), 2008). Multiple freeze-thaw cycles also seem to be 
successful at achieving cell death by repeated injury and ischemia to the tissue (Fergany, 2005; 
Lehman & Landman, (I), 2008). 
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Tumor location remains of high importance when evaluating a patient for percutaneous 
ablations. Patients with tumors that are near blood vessels tend to be poor candidates of 
radiofrequency ablations because of the heat sink effect. Renal cell carcinomas also tend to have 
a great deal of blood flow themselves, which absorbs the heat from the radiofrequency probe. To 
make the procedure more successful, many physicians are using a method of renal arterial 
embolization to reduce blood flow throughout the tumors (Arima, Yamakado, Kinbara, et aI., 
2007). By doing this, less heat is dissipated which allows the tumor to reach a higher central 
temperature and provides a better chance of tumor necrosis (Arima, Yamakado, Kinbara, et aI., 
2007). When performing percutaneous ablations it is also important to be precise with the 
placement of the probe so that no ureters or other surrounding organs are harmed. Certain 
techniques such as injecting contrast medium into the ureters, placing a ureteral stent with cold 
saline, and injecting saline or carbon dioxide into the retroperitoneal cavity all aid in the 
separation of the ureters and the tumor so no injury is inflicted on the ureters (Arima, Yamakado, 
Kinbara, et aI., 2007). Guidance of the probe also becomes crucial during percutaneous 
radiofrequency and cryoablations. Navigation of the probes is generally performed under the 
guidance of computed tomography or magnetic resonance imaging. While ultrasound has the 
ability to be used in both ablation procedures, it is not recommended during radiofrequency 
ablations due to the poor image quality caused by steam bubbles that are produced from the 
vaporization during the procedure (Boss, Clasen, Kuczyk, et aI., 2007). Magnetic resonance 
imaging is preferred during a radio frequency procedure because of the ability to produce images 
with high soft tissue contrast (Boss, Clasen, Kuczyk, et aI., 2007). During a cryoablation 
procedure, axial imaging using magnetic resonance and computed tomography is used to monitor 
the formation ofthe hypo-dense ice ball (Lehman & Landman, (2), 2008). Being able to 
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visualize this ice ball throughout the procedure insures the total ablation of the tumor (Lehman & 
Landman, (1), 2008; Lehman & Landman, (2), 2008). 
There are a few risk factors of percutaneous ablations, however. One of the risk factors is 
damage to healthy tissue adjacent to the tumor by the conductance of heat or bitter cold from the 
probe during the procedures. Although measures are taken to protect surrounding organs and 
healthy tissue, it is inevitable that some healthy tissue around the tumor will die. Another 
disadvantage is that the ablated tumors stay in situ, which could possibly cause a relapse 
(Lehman & Landman, (1), 2008; Boss, Clasen, Kuczyk, et a!., 2007). This stresses that the 
importance of follow-up imaging after a percutaneous ablation is crucial to determine the 
effectiveness of the procedure. Post-RF A syndrome is a documented complication associated 
with percutaneous radiofrequency ablations. This occurs in approximately 40 percent of all 
cases, resulting in flu-like symptoms accompanied by a fever, with symptoms resolving within a 
couple days (Fergany, 2005). Another disadvantage of percutaneous radiofrequency ablations is 
that it tends to be more painful than cryoablations (Permpongkosol, Nielsen, & Solomon, 2006). 
While both radiofrequency ablations and cryoablations are usually performed under conscious 
sedation, the decreased amount of pain for a cryoablation procedure allows procedures to be 
done on an outpatient basis, which is more cost effective (Permpongkosol, Nielsen, & Solomon, 
2006). However, blood loss during a percutaneous radio frequency procedure is less than a 
cryoablative procedure because the heat from the probe cauterizes the blood vessels throughout 
the ablation (Park, Anderson, & Matsumoto, 2006). In addition, in some cases it takes more than 
one cryoablation procedure to be fully successful at ablating the tumor (Breen, Rutherford, 
Stedman, et ai, 2007). A study conducted by Breen, Rutherford, Stedman, et al (2007), noted a 
failure rate of 12.5 percent following the first initial treatment utilizing percutaneous 
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cryoablation. However, after a retreatment, the cancer-free success rate skyrocketed to 97.5 
percent. This indicates that patients should be aware that it may take more than one treatment to 
fully eliminate the renal cell carcinoma. In a multi-institutional study, a total of271 cases were 
analyzed and only one death (1.8 percent) was documented which was caused by aspiration 
pneumonia that was not directly linked to the cryoablation ablation (Breen, Rutherford, Stedman, 
et aI, 2007). The only other major complication involved a patient hemorrhaging to the 
extensiveness that required a blood transfusion. The most common minor complication 
following the percutaneous ablative therapies in this study was pain at the probe insertion site 
which was present in only 9.8 percent of the cases. While there are some disadvantages for 
percutaneous ablative procedures, the complication rates for them are fairly low. 
Objectives 
The purpose of this study is to compare the efficacy of percutaneous radiofrequency 
ablations and percutaneous cryoablations of renal cell carcinoma in terms ofthe pain associated 
with each procedure as measured by the amount of conscious sedation required; the amount of 
post-operative medication required; and the length oftime required to perform the procedure. 
Research Questions 
I. Is there a difference in the amount of intra-operative analgesics administered during a 
percutaneous radiofrequency ablation and a percutaneous cryoablation? 
2. Is there a difference in the length of a percutaneous cryoablation and a percutaneous 
radiofrequency ablation procedure? 
3. Is there a difference in the amount of post operative analgesics administered following a 
percutaneous cryoablation and a percutaneous radiofrequency ablation? 
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Definitions 
Renal cell carcinoma- a tumor of the kidneys 
Cryoablation- procedure in which probes are inserted into a tumor site and argon gases and 
nitrogen gases are introduced into the core of the tumor causing tumor death 
Radiofrequency ablations- a procedure in which probes are inserted into a tumor site and an 
electrical current is induced into the tumor, heating it up, and eventually causing tumor death 
Conscious sedation- an altered state of consciousness induced by anesthesia and pain 
medications that reduces the amount of pain and discomfort for a patient 
Analgesics- medications administered to reduce patient discomfort and pain 
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Chapter 2 
Methodology 
This is a retrospective analysis of patient data related to percutaneous cryoablations and 
radiofrequency ablations for the treatment of renal cell carcinoma. The data was a convenience 
sample obtained from an existing patient database collected by Riverside Radiology Inc. This 
study was approved by The Ohio State University Internal Review Board. 
The nominal independent variables in this study are the methods used for tumor ablation: 
radiofrequency ablation and cryoablation. The dependent variables in this study are: the length 
oftime required to complete the procedure, amount of intra-operative analgesics (mg morphine 
converted dose) administered, and the amount of post-operative analgesics (mg morphine 
converted dose) administered. 
Population and Sample 
The sample consisted of 34 patients over the age of 18 who had undergone a renal cell 
carcinoma percutaneous radiofrequency ablation or a percutaneous cryoablation at Riverside 
Methodist Hospitals from April 2009 to December 20 I O. All patients meeting the criteria were 
originally included in the study, however, when collecting data it was found that there were 
significantly more radiofrequency ablations performed compared to cryoablations. Thus, in order 
to allow for an equal comparison, eight of the last radiofrequency ablations were randomly 
eliminated from the analysis. 
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Design 
This was a retrospective analysis of an existing patient database provided by Riverside 
Methodist Hospital, Columbus, Ohio. No directly identifiable patient data was obtained. For 
data analysis, the independent variables were coded as Xl~ radiofrequency ablations and X2= 
cryoablations. The length of time required to complete each procedure was measured in minutes 
and recorded. To allow analysis as in interval dependent variable, data obtained in reference to 
the length of procedure was categorized in the following time ranges: 1 = 40-49 min; 2= 50-59 
min; 3= 60-69 minutes; 4= 70-79 minutes; 5= 80-89 minutes; 6= 90 or more minutes. The 
amounts of intra-operative and post-operative analgesics administered for each patient were 
recorded. Since the actual medications utilized varied by patient and interventional radiologist, 
the analgesic doses were converted to a standard measurement, milligrams of morphine. A 
research coordinator in the College of Pharmacy at The Ohio State University was consulted and 
he provided a standardized narcotic converter chart supplied by MedCalc to allow for easier 
comparison as ratio variables. 
Data Analysis 
A variation of a Pearson R statistical analysis known as a point bi-serial analysis was 
conducted to examine the relationship between the two nominal, independent variables (Xl= 
radiofrequency ablations, and X2= cryoablations) and the dependent variable, procedure length. 
A Chi-Square test of significance was used to evaluate the relationship between the two nominal, 
independent variables (Xl~radiofrequency ablations, and X2= cryoablations) and the dose of 
intra-operative analgesics and post-operative analgesics administered using a standard converted 
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dose of mg. of morphine. An a priori value = .05 to evaluate the level of significance between all 
of the variables. 
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Chapter 3 
Results 
This study consisted of34 patients who had a percutaneous ablative therapy performed 
for the treatment of renal cell carcinoma at Riverside Methodists Hospitals, Columbus, Ohio. Of 
the 34 procedures that were studied, 19 (55.9%) were percutaneous radiofrequency ablations, 
and 15 were cryoablations (44.1%) (Table 1). 
The doses of intra-operative analgesics administered to patients undergoing a 
radiofrequency ablation ranged from 30 mg. morphine to 120 mg. morphine, with a median dose 
of 60 mg. morphine, and a mean dose of 65 .13 mg. morphine. One case required a dose of 120 
mg. morphine which slightly skewed the mean. If this patient is not included in the sample, the 
median dose is remains 60 mg morphine and the mean dose is 62.08 mg. morphine. The doses 
of intra-operative analgesics administered to patients for a cryoablation ranged from 15-95 mg. 
morphine with a median dose of 82.5 mg. morphine and a mean dose of90.55 mg. morphine 
(Table 3). Although the differences in the administered dose of intra-operative analgesics were 
not statistically significant, the mean dose of intra-operative analgesics administered during the 
cryoablation procedures is approximately 30% higher than the analgesic dose required during the 
radiofrequency ablation procedures, eliminating the outlying value, suggesting that a significant 
finding may exist when studying a larger sample. 
The doses of post-operative analgesics given to patients undergoing a radiofrequency 
ablation ranged from 0-42.3 mg. morphine with a median of 1 0 mg. morphine and a mean of 
10.86 mg. morphine. The amounts of post-operative analgesics administered to patients 
receiving a cryoablation ranged from 0-61.5 mg. morphine with a median of7.7 mg. morphine 
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and a mean of 12.15 mg. morphine (Table 4). There were nine patients in this study that did not 
receive any post-operative analgesics. Five ofthe nine underwent a radiofrequency ablation, 
while the remaining four received a cryoablation procedure. 
The length of time required to perform the radiofrequency ablation procedures ranged 
from 40 to 80 minutes with a median of 59 minutes and a mean of 59.74 minutes. The length of 
time required to perform the cryoablation procedures ranged from 50 to 150 minutcs, with a 
median of95 minutes, and a mean of 101.33 minutes (Table 5). 
1. Is there a difference in the amount of intra-operative analgesics during a percutaneous 
radiofrequency ablation and a percutaneous cryoablation? (p~. 05) 
The dose of intra-operative analgesics administered for all 34 patients was recorded and 
converted to a standard measurement, milligrams of morphine. A chi-square test of significance 
was performed to compare the two ablation procedures. Using a prior value of (p~.05) the 
analysis yielded an X2 ~ 15.651 (df~ 14). Using Table IV of Fisher and Yates: Statistical Tables 
for Biological and Agricultural and Medical Research, the p~.05 value shows 23.685 as the value 
for comparison. Since 20.466 is not greater than 23.685, it was found that there is no level of 
significance bctween the nominal, independent variables and the amount of intra-operative 
analgesics (Table 5). 
FINDINGS: There was no significant difference in the amount of intra-operative 
analgesics given during percutaneous radiofrequency ablations and percutaneous 
cryoablations in the treatment of renal cell carcinoma. 
2. Is there a difference in the length of procedure during a percutaneous cryoablation and a 
percutaneous radiofrequency ablation? (p~.05) 
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The length of procedure for each of the 34 patients that underwent an ablative therapy for 
the treatment of renal cell carcinoma was recorded. A point bi-serial analysis was conducted to 
examine the relationship between the two independent variables and the procedural lengths 
resulting in R = .719, (df=13). The critical value using a prior value of .05 is .6411 indicating a 
significance between the two independent variables and the procedure lengths (Table 6). After 
further analyzing the data, it was found that percutaneous cryoablations took significantly longer 
to complete compared to percutaneous radiofrequency ablations (Figure 1). 
FINDINGS: In regards to the treatment of renal cell carcinoma, the length of a 
percutaneous cryoablation is significantly longer than a percutaneous radiofrequency 
ablation. 
3. Is there a difference in the amount of post operative analgesics used after a percutaneous 
cryoablation and a percutaneous radiofrequency ablation? (p=.05) 
The dose of post-operative analgesics administered was recorded for all 34 patients 
included in this study and converted to a standard measurement, milligrams of morphine. A chi-
square analysis was performed to examine any levels of significance between the two nominal, 
independent variables (X,= radio frequency ablations, X2= cryoablations) and the amount of post-
operative analgesics. The chi-square test of significance yielded a value of 13.76 (df= 5) at an a 
priori level of (p=.05). Referring table IV of Fisher and Yates: Statistical Tables for Biological, 
Agricultural and Medical Research, the distribution ofX2 number was 16.92. Since the X2 value 
of 13.76 was lcss than 16.92 (Table 7), there is no significant difference in the amount of post-
operative analgesics administered to a patient for a percutaneous radiofrequency ablation or a 
cryoablation. 
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FINDINGS: There is no significant difference in the amount of post-operative analgesics 
given for a percutaneous radiofrequency ablation or cryoablation for the treatment of 
renal cell carcinoma. 
Discnssion 
In searching for a gold standard in the percutaneous treatment ofrenal cell carcinoma, 
this study primarily focused on length of procedure and the doses of intra-operative and post-
operative analgesics administered to patients who went through a percutaneous radiofrequency 
ablation or cryoablation at Riverside Methodist Hospital. 
The length of time required to perform each procedure is used to examine the ease and 
speed of which each of these procedures could be completed. This is an important factor 
considering that many ofthe patients receiving a percutaneous ablative therapy for the treatment 
of renal cell carcinoma have multiple comorbidities. Many ofthese patients have trouble 
breathing and cannot withstand lying supine for long periods oftime without an overall decline 
in his/her health status. Minimizing the procedure time allows the patient to be moved to the 
recovery area more quickly, allowing them to be placed in a more comfortable position to rest 
and recover. Reducing the procedure time also allows for human resources such as physicians, 
technologists, and nurses, as well as equipment resources, to be used in a more efficient manner. 
This increases the availability of all resources to be used to their full potential. A faster 
procedure allows that patient to get to recovery in a shorter time, allowing them to rest and 
recover in a better environment. 
There are some factors that may affect the promptness at which a percutaneous procedure 
can be performed, however. Research conducted by Park, Anderson, & Matsumoto (2006) noted 
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that tumors situated anteriorly within the body were difficult to ablate due to fear of injuring a 
bowel, organ, or ureter. This can infer that if some of these patient's tumors in this study were 
situated anteriorly or near a vital organ such as small intestines or ureters, the time it takes for 
that procedure to be completed may be increased due to the location of the tumor within the 
kidney. The size of the tumor can also have an effect on the time it takes to complete an 
ablation. According to Arima, Yamakado, Kinbara, et. al (2007), tumors greater than 4 em in 
size may require multiple ablation sequences. It can then be inferred that a tumor large in 
diameter would require multiple ablations and this factor could definitely increase the length of 
time required to complete the ablation procedure. Due to the limitation of the database utilized 
for this study, there was no comparison of tumor size and locations. 
This study utilized the administered dose of analgesics in mg morphine converted dose 
during the ablative procedure, and following the ablative therapy as an indication of the pain 
levels correlated with the two types of ablative therapies. A multi-institutional study conducted 
by Permpongkosol, Nielsen, and Solomon (2006) demonstrated that percutaneous 
radiofrequency ablations tended to be more painful to a patient than a cryoablation procedure. 
However, our study of a convenience sample did not demonstrate a significant difference in the 
analgesic dose of intra-operative or postoperative analgesics utilized by the type of ablative 
therapy. Therefore we could not replicate the findings made by Pennpongkosol, Nielsen, and 
Solomon (2006). 
Limitations and Further Research 
One of the most predominant limitations in this study was the sample size. The small 
sample size greatly reduces the statistical power in this study. It is recommended that parametric 
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statistics should not be used on a sample size less than 20. It was originally believed that 
approximately 50 patients would be available for this study in the existing database, allowing a 
comparison of 25 patients in each ablative procedural category. However, while collecting the 
data for this study, it was found that the quantity of radio frequency ablations significantly 
outnumbered the quantity of per cutaneous cryoablations performed at Riverside Methodist 
Hospital. Therefore a sample of25 patients undergoing a cryoablation could not be obtained. 
This limited the total sample available for an equal comparison. The small patient database can 
be associated to the fact that percutaneous ablative therapies for the treatment of renal cell 
carcinomas are still a fairly new procedure. Perhaps another study can be conducted in the fi.lture 
as the patient database continues to increase. 
Another limitation of this study is that the ablations were performed by more than one 
interventional radiologist. Perhaps analyzing ablative therapies performed by multiple 
physicians allows for some bias as to the speed at which a specific physician works and how 
freely they prescribe medications. In future studies it may be beneficial to include the number of 
interventional radiologists performing the study as a dependent variable to improve the external 
validity of the findings. 
As mentioned above, the tumor size and location is also another extraneous variable 
which was not controlled in this study. In future studies it may be beneficial to include tumor 
size and location as dependent variables. 
20 
References 
Arima, K., Yamakado, K., Kinbara, H., et al. (2007). Percutaneous radio frequency ablation with 
transarterial embolization is useful for treatment of stage I renal cell carcinoma with surgical 
risk: Results at 2-year mean follow-up. International Journal of Urology, 14(7),585-590. 
Boss, A., Clasen, S., Kuczyk, M. et al. (2007). Image-guided radiofrequency ablation of renal 
cell carcinoma. European Radiology, 3, 725-733 
Breen, DJ., Rutherford, E.E., Stedman, B., et al. (2007). Management of renal tumors by image-
guided radiofrequency ablation: Experience in 105 tumors. Cardiovascular Interventional 
Radiology. 30, 936-942. 
Cohen, H.T. and McGovern, FJ. (2005). Renal-cell carcinoma. The New England Journal of 
Medicine, 353(23), 2477-2490. 
Fergany, A. (2005). Current status and advances in nephron-sparing surgery. Clinical 
Genitourinwy Cancer, 5, 26-33. 
Lehman, D.S. and Landman, J. (2008) Kidney cancer ablative therapy: Indications and patient 
selection. Current Urology Reports, 9(1), 34-42. 
Lehman, D.S. and Landman, J. (2008). Cryoablation and radio frequency for kidney tumor. 
Current Urology Reports, 9(2), 128-134. 
Park, S., Anderson, lK, Matsumoto, E.D., et al. (2006). Radiofrequency ablation of renal 
tumors: Intermediate-term results. Journal of En do urology, 20(8), 569-573. 
Permpongkosol, S., Nielsen, M.E., and Solomon, S.B. (2006). Percutaneous Renal Cryoablation. 
Urology, 68(1), 19-25. 
21 
Table I - Frequency of Ablation Procedures 
Frequency Percent Valid Percent Cumulative 
Percent 
Radiofrequeucy 
Ablations 19 54.3 54.3 54.3 
Cryoablations 
15 42.9 42.9 100.0 
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Table 2 - Frequency of Intra-operative Analgesics 
Amount of Intra-
operative Analgesics 
(mg morphiue) 
Procedure 
RF 1 60 
RF2 75 
RF3 120 
RF4 75 
RF 5 45 
RF6 45 
RF7 52.5 
RF 8 90 
RF9 75 
RFI0 75 
RF 11 75 
RF 12 30 
RF 13 30 
RF14 52.5 
RF 15 105 
RF16 60 
RF 17 60 
RF 18 75 
RF19 37.5 
Cryo 1 112.5 
Cryo 2 97.5 
Cryo 3 75 
Cryo 4 90 
Cryo 5 60 
Cryo 6 60 
Cryo 7 45 
Cryo 8 15 
Cryo 9 105 
Cryo 10 60 
Cryo 11 45 
Cryo 12 90 
Cryo 13 135 
Cryo 14 195 
Cryo 15 82.5 
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Table 3-Frequencies ofIntra-operative Analgesics 
Milligrams of Morphine Converted Dose 
Procednre Mean Median Range 
Radiofrequency 65.13 90.00 30.00-120.00 
Ablations 
Cryoablatious 90.55 82.50 15.00-95.00 
Table 4-Frequencies of Post-operative Analgesics 
Milligrams of Morphine Converted Dose 
Procedure Meau Median Rauge 
Radiofrequency 10.86 10.00 0.00-42.3 
Ablations 
Cryoablations 12.15 7.70 0.00-61.50 
Table 5-Frequencies of Lengths of Procedure 
Procedure Lengths in Minutes 
Procednre Mean Median Range 
Radiofrequency 59.74 59 40-80 
Ablations 
Cryoablations 101.33 95 50-150 
24 
Table 6 - Freguencies of Post-operative Analgesics 
Amount of Post-
operative Analgesics 
(mg morphine) 
Procedure 
RF I 20.0 
RF2 0.0 
RF 3 10.0 
RF4 14.0 
RF 5 10.0 
RF 6 0.0 
RF 7 10.0 
RF 8 10.0 
RF 9 20.0 
RF 10 10.0 
RF II 0.0 
RF 12 20.0 
RF 13 10.0 
RF 14 0.0 
RF 15 10.0 
RF16 10.0 
RF17 10.0 
RF 18 42.3 
RF19 0.0 
Cryo I 7.7 
Cryo 2 23.1 
Cryo 3 0.0 
Cryo4 7.7 
Cryo 5 10.0 
Cryo 6 7.7 
Cryo 7 10.0 
Cryo 8 0.0 
Cryo9 10.0 
Cryo 10 10.0 
Cryo II 30.8 
Cryo 12 0.0 
Cryo 13 61.5 
Cryo 14 3.8 
Cryo 15 0.0 
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Table 7 - Frequencies of Length of Procedure 
Length of Procedure 
Length of Procedure (Minutes) Totals 
Procedure 40-49 50-59 60-69 70-79 80-89 90 or + 
RF 3 6 5 2 3 0 19 
Cryo 0 I 0 I 5 8 IS 
Totals 3 7 5 3 8 8 34 
Table 8- Chi-Square Test ofIntra-operative Analgesics 
Value df Asymp. Sig. 
(2-sided) 
Pearson Chi-Sqnare 15.651a 14 .335 
Likelihood Ratio 20.466 14 .116 
N of Valid Cases 34 
.. 
a. 30 cells (100.0%) have expected count less than 5. The mInImum expected 
count is .44. 
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Table 9- Serial Bi-point Test of Significance for Length of Procedure 
Procedure Procedure Length 
Procedure Pearson Correlation 1 .719 
Sig. 2 (2-tailed) .000 
N 34 34 
Procedure Pearson Correlation .719 1 
Length 
S ig. 2 (2-tailed) .000 
N 34 34 
"Correiatlon IS sIgmficant at the 0.01 level (2-tatled). 
Table 10- Chi-Square Analysis of Post-operative Analgesics 
Value df Asymp. Sig. 
(2-sided) . 
Pearson Chi-Square 13.754a 9 .131 
Likelihood Ratio 18.249 9 .032 
N of Valid Cases 34 
. . 
a. 17 cells (85.0%) have expected count less than 5. The mInImum expected count IS .44 . 
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